Clinical Trials Logo

Clinical Trial Summary

Background: Niemann-Pick type C (NPC) disease is a rare, progressive neurodegenerative disease that affects mainly the brain, liver, and spleen but also other parts of the body. There is no cure for NPC, and symptoms only get worse over time. Symptoms can include seizures, difficulty moving or talking, or dementia. But symptoms can vary among different people with the disease. Some may have seizures, while others do not, for example. Some people begin showing symptoms in childhood; in others, symptoms may not appear until they are adults. Researchers want to learn more about why NPC affects people differently. This natural history study will gather data from people with NPC in order to understand more about the disease and how it affects the body. Objective: This study will create the first and largest database about NPC. Eligibility: People of any age who have NPC. Design: Participants will have blood drawn from a vein. This will happen only once. The blood will be used to analyze the participants DNA. The participants medical records will be reviewed. The study team will collect data on participants NPC diagnosis and symptoms; they will record how long participants have had each symptom. The study team will also collect data on each participants age, sex, race, height, weight, medications, and other test results. The study team will communicate with participants. They will discuss the study and answer any questions. Participants will receive up to $190.


Clinical Trial Description

Study Description: The primary objective of this protocol is to investigate the phenotypic heterogeneity of NPC by using clinical and genomic data, and to establish a comprehensive database to facilitate future investigations. Objectives: 1. Identify correlations between NPC clinical phenotypic findings and genomic markers to facilitate the understanding of the heterogeneity of this disease. 2. Identify genetic contributions to NPC disease progression that can be utilized as potential therapeutic targets. 3. Establish the first and largest database of genomic and phenotypic information for NPC to benefit the NPC research and patient community. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05588167
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Derek Alexander
Phone (301) 827-0387
Email derek.alexander@nih.gov
Status Recruiting
Phase
Start date November 28, 2022
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT03759639 - N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) Phase 2
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Completed NCT02435030 - A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C N/A
Completed NCT02534844 - VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease Phase 2/Phase 3
Withdrawn NCT03687476 - Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease Phase 2
Enrolling by invitation NCT05368038 - ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Completed NCT01899950 - Longitudinal Study of Cognition With Niemann-Pick Disease, Type C N/A
Terminated NCT00668564 - Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Phase 2
Active, not recruiting NCT05163288 - A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C Phase 3
Active, not recruiting NCT02612129 - Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C Phase 2/Phase 3
Recruiting NCT03471143 - Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C Phase 1/Phase 2
Terminated NCT04958642 - Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease Phase 2/Phase 3
Terminated NCT03879655 - Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1 Phase 2/Phase 3
Completed NCT00975689 - Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Phase 1/Phase 2
Withdrawn NCT01306604 - Biomarker for Niemann Pick Type C Disease (BioNPC)
Recruiting NCT00344331 - Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Active, not recruiting NCT05758922 - Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease Phase 2
Completed NCT03910621 - Safety and Efficacy of Miglustat in Chinese NPC Patients Phase 4
Available NCT04316637 - Early Access Program With Arimoclomol in US Patients With NPC